Does reduced liver conversion of cholesterol to bile acids raise LDL cholesterol?

The liver is the primary organ for maintaining systemic cholesterol homeostasis, utilizing the synthesis of bile acids as its main pathway for irreversible cholesterol disposal.

Hepatic conversion and disposal

• Daily clearance rates: Under normal physiological conditions, the liver clears approximately 200 to 600 mg of cholesterol daily by converting it into primary bile acids, predominantly cholic and chenodeoxycholic acids.
• Enzymatic control: This pathway is governed by the liver-specific enzyme cholesterol 7α-hydroxylase (CYP7A1), which mediates the rate-limiting step of the classical pathway, accounting for 90% to 95% of total bile acid production in healthy adults.

Mechanistic pathways

• Intracellular accumulation: Decreased conversion of cholesterol to bile acids causes an accumulation of intracellular cholesterol within hepatocytes.
• Receptor downregulation: This hepatic accumulation inactivates sterol regulatory element-binding proteins (SREBPs). Inactivation of SREBPs downregulates the transcription and surface expression of hepatic LDL receptors (LDLR).
• Impaired clearance: Because LDL receptors are responsible for clearing LDL particles from the bloodstream, a reduction in their expression impairs plasma clearance, directly elevating circulating LDL cholesterol.

Clinical and genetic evidence

• Loss-of-function mutations: In humans, homozygous loss-of-function mutations in the CYP7A1 gene result in CYP7A1 deficiency, a rare monogenic disorder characterized by severe hypercholesterolemia and high LDL cholesterol levels that are resistant to standard statin therapy.
• Therapeutic validation: Interventions that interrupt the enterohepatic circulation of bile acids, such as bile acid sequestrants, stimulate hepatic bile acid synthesis, deplete liver cholesterol pools, upregulate LDL receptors, and successfully lower circulating LDL cholesterol.

Bottom line

• Decreased conversion of hepatic cholesterol to bile acids impairs the body's primary elimination pathway, triggering a cascade that downregulates LDL receptors and directly raises circulating LDL cholesterol levels.